FCGR3B and breast carcinoma: The second relationship was not completely new and has already been raised by another group that have shown a significant correlation between the frequency of CD56+CD16+ effector lymphocytes among PBMCs and ADCC induced by in vitro addition of trastuzumab in patients with operable breast cancer overexpressing HER2, before and after therapy with trastuzumab (70).